Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AMS vs TOI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TOI Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–5 Matrix Metrics)

TOI Overall Winner 6-Pillar Tally: AMS 3 – 3 TOI Matrix Metrics: AMS 5 – 5 TOI

As of Nov 16, 2026, The Oncology Institute, Inc. (TOI) is the stronger overall head-to-head candidate over American Shared Hospital Services (AMS) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). AMS carries a Unified Composite Score of 33.8/100 (SELL) at $1.07 (44.6x Forward P/E, -7.4% operating margin), whereas TOI carries 53.5/100 (HOLD) at $5.13 (N/M Forward P/E, -4.4% operating margin).

  • Technical & Structure Timing Caution: AMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1); meanwhile TOI trades in a Neutral technical trend (SURGE options phase, RSI 48.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AMS vs TOI
AMS NYSE American
American Shared Hospital Services
Services-Medical Laboratories
$1.07
-0.93% 1D
Market Cap $7.2M
TTM Revenue $30M
Forward P/E 44.6x
Beta / 30D Vol 0.18β · 46% Vol
Unified Composite Score
33.8 / 100 SELL
Tech 24.0 Fund 38.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.9%), weak momentum, RSI 27
RSI-14: 27.1 · SMA20: $1.21 · SMA50: $1.32
TOI NASDAQ Head-to-Head Winner
The Oncology Institute, Inc. Common Stock
Services-Offices & Clinics Of Doctors Of Medicine
$5.13
+5.56% 1D
Market Cap $506.9M
TTM Revenue $546M
Forward P/E N/M
Beta / 30D Vol 1.66β · 73% Vol
Unified Composite Score
53.5 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 48.6 · SMA20: $5.41 · SMA50: $5.16

6-Pillar Scorecard Institutional Category Breakdown (AMS 3 – 3 TOI)

Columns: Metric · AMS · TOI
1. Valuation Multiples AMS
Forward P/E 44.6x N/M
Trailing P/E 44.6x N/M
PEG Ratio N/M N/M
EV / Revenue 0.8x 1.0x
2. Growth & Scale TOI
Revenue Growth (YoY) +19.2% +41.2%
Earnings Growth (YoY) -38.1% +0.0%
TTM Revenue (USD) $30M $546M
Market Cap $7.2M $506.9M
3. Profitability & Quality AMS
Gross Margin 34.8% 15.1%
Operating Margin -7.4% -4.4%
Net Profit Margin -5.8% -8.0%
Return on Equity (ROE) -12.1% -651.7%
4. Balance Sheet & Cash Flow TOI
Cash Generation (TTM) -$916,000 -$3.3M
Cash Flow Margin -3.0% -0.6%
Net Cash / Leverage $17M Net Debt (0.95x D/E) $63M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TOI
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile N/A (N/A) 80.2% (35th %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat AMS
OpEx & R&D Intensity 42.2% of Rev ($13M) 19.5% of Rev ($106M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AMS (5) vs TOI (5)
Institutional Metric AMS TOI Criterion Row Edge
Market Capitalization
Scale
$7.2M $506.9M Larger Scale TOI
Trailing P/E Ratio
Valuation
44.6x N/M Lower Multiple AMS
Forward P/E Ratio
Valuation
44.6x N/M Lower Multiple AMS
Revenue Growth (YoY)
Growth
+19.2% +41.2% Higher Growth TOI
Operating Margin (TTM)
Profitability
-7.4% -4.4% Higher Margin TOI
Net Profit Margin
Profitability
-5.8% -8.0% Higher Margin AMS
Return on Equity (ROE)
Capital Efficiency
-12.1% -651.7% Higher ROE AMS
52-Week Range Position
Momentum
6% ($1–$2) 65% ($2–$7) Stronger Trend TOI
Beta / 30D Volatility
Risk Regime
0.18β · 46% Vol 1.66β · 73% Vol Lower Realized Risk AMS
Unified Institutional Score
Composite Signal
33.8 / 100 (SELL) 53.5 / 100 (HOLD) Higher Composite TOI
Trailing 12M Revenue (USD)
Operating Scale
$30M $546M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
34.8% 15.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.8x EV/Rev N/M PEG · 1.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$916,000 ($17M Net Debt (0.95x D/E)) -$3.3M ($63M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AMS +2.5 pp
AMS: -0.34% · TOI: -2.84%
3M Horizon TOI +39.32 pp
AMS: -12.65% · TOI: +26.67%
6M Horizon TOI +119.25 pp
AMS: -29.95% · TOI: +89.3%
1Y Horizon TOI +100.27 pp
AMS: -33.71% · TOI: +66.56%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AMS Revenue TOI Revenue AMS Op. Margin TOI Op. Margin Margin Leader
FY2018 $20M N/A 9.4% N/A AMS
FY2019 $20M N/A 7.5% N/A AMS
FY2020 $20M $190M -53.1% -4.4% TOI
FY2021 $20M $200M 7.7% -22.6% AMS
FY2022 $20M $250M 12.3% -32.5% AMS
FY2023 $20M $320M 1.3% -23.8% AMS
FY2024 $30M $390M -9.9% -15.3% AMS
FY2025 $30M $500M -12.8% -7.2% TOI

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AMS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AMS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TOI SURGE
14d in phase · OBV DISTRIBUTION
Current IV 80.2%
IV Percentile 35th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact TOI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AMS Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $7.2M market capitalization and -7.4% operating margin.
OpEx & R&D Reinvestment 42.2% of Rev ($13M)
90D Engineering Disclosures 0 Published
Mapped Supply-Chain Ecosystem (18 partners):
Taiwan Semiconductor Manufacturing Company GlobalFoundries ASE Technology Holding Amkor Technology
TOI Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $506.9M market capitalization and -4.4% operating margin.
OpEx & R&D Reinvestment 19.5% of Rev ($106M)
90D Engineering Disclosures 0 Published

Investor FAQ AMS vs TOI Key Questions & Quantitative Answers

As of Nov 16, 2026, The Oncology Institute, Inc. (TOI) is the stronger overall head-to-head candidate over American Shared Hospital Services (AMS) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). AMS carries a Unified Composite Score of 33.8/100 (SELL) at $1.07 (44.6x Forward P/E, -7.4% operating margin), whereas TOI carries 53.5/100 (HOLD) at $5.13 (N/M Forward P/E, -4.4% operating margin). Technical & Structure Timing Caution: AMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1); meanwhile TOI trades in a Neutral technical trend (SURGE options phase, RSI 48.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TOI leads the Growth & Scale pillar: AMS posts +19.2% YoY revenue growth and -38.1% YoY earnings growth on $30M TTM revenue (34.8% gross margin, -7.4% operating margin), compared with TOI at +41.2% YoY revenue growth and +0.0% YoY earnings growth on $546M TTM revenue (15.1% gross margin, -4.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AMS cumulative revenue shifted +50.0% while TOI shifted +163.2%. In operating R&D and SG&A reinvestment, AMS deploys 42.2% of Rev ($13M) (0 90-day corporate R&D disclosures) versus 19.5% of Rev ($106M) (0 disclosures) for TOI.

AMS screens cheaper on headline valuation multiples. AMS trades at 44.6x Forward P/E, 44.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-3.0% FCF margin), whereas TOI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.0x EV/Revenue (-0.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AMS (-12.1% ROE) versus TOI (-651.7% ROE) capital efficiency.

In options market volatility and institutional positioning, AMS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.18β · 46% Vol realized risk). By comparison, TOI carries 80.2% implied volatility (35th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (1.66β · 73% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.